A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT06329206 |
|
Recruitment Status :
Recruiting
First Posted : March 25, 2024
Last Update Posted : April 3, 2024
|
Sponsor:
Suzhou Genhouse Bio Co., Ltd.
Collaborators:
Zhejiang Cancer Hospital
Henan Cancer Hospital
Hubei Cancer Hospital
The First Affiliated Hospital of Zhengzhou University
Information provided by (Responsible Party):
Suzhou Genhouse Bio Co., Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | April 25, 2026 |
| Estimated Study Completion Date : | September 1, 2026 |